Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals
SAN MATEO, Calif.–(BUSINESS WIRE)–Evidation, the leader in direct-from-participant real-world data and health research, is announcing new preliminary insights suggesting that nearly 1 in 7 injectable GLP-1 users are microdosing, that microdosing is largely patient-driven, and that there are multiple relevant influences driving microdosing decisions. Evidation has been conducting ongoing, multimodal, participant-consented research within a discrete […]
Shed Launches Three New Wellness Solutions: Microdose GLP-1, NAD+ and Glutathione for Energy, Clarity, and Healthy Aging
SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ — Shed, the wellness brand known for health and weight-loss solutions, has launched three new products to support long-term health: Tirzepatide Microdose GLP-1 injections, oral NAD+ tablets and Glutathione injections. These offerings build on…
IJMS, Vol. 26, Pages 12130: The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition
IJMS, Vol. 26, Pages 12130: The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition International Journal of Molecular Sciences doi: 10.3390/ijms262412130 Authors: Lampros Chrysavgis Niki Gerasimoula Mourelatou Maria-Evangelia Koloutsou Sophia Rozani Evangelos Cholongitas Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer incretin-based co-agonists have transformed obesity and type 2 […]
Cells, Vol. 14, Pages 2009: Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice
Cells, Vol. 14, Pages 2009: Liraglutide-Driven Weight Loss Modulates Placental Remodeling in Obese Pregnancies in Mice Cells doi: 10.3390/cells14242009 Authors: Natassia Rodrigo Dunja Aksentijevic Nikayla Patel Carol A. Pollock Lana McClements Sarah J. Glastras Background: The placenta stands at the maternal–fetal interface and is a key organ regulating the intrauterine environment. In pregnancies exposed to […]
Are Doctors Trained To Treat Obesity? Dr. Scott Kahan On GLP-1 & Public Health | RAISING AMERICA
In this episode of Raising America, Elizabeth Prann sits down with Director of the National Center for Weight and Wellness, Scott Kahan. He is a physician trained in clinical medicine and public health and an internationally recognized specialist in Obesity Medicine. He is Director of the National Center for Weight and Wellness and has held […]
GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top Research
(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes. In a phase III trial…
Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process
Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process Pharmaceuticals doi: 10.3390/ph18121896 Authors: Rolan R. Shaifutdinov Maria V. Sinegubova Ivan I. Vorobiev Polina E. Prokhorova Alexey B. Podkorytov Nadezhda A. Orlova Background: Dulaglutide, a GLP-1-IgG4 Fc fusion, is a long-acting GLP-1 receptor agonist […]
OrsoBio obesity data; Monte Rosa’s prostate cancer pill; Development pacts for Adaptive and SandboxAQ
Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide, OrsoBio’s oral obesity drug TLC-6740 led to an additional …
Popular weight-loss drugs may lower cancer risk, finds large study
Exciting new findings indicate that GLP-1 weight-loss medications might dramatically reduce the likelihood of 10 types of cancer linked to obesity for patients with type 2 diabetes, outperforming insulin. However, there’s no observed benefit for postmenopausal breast or thyroid cancers.
Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing
BOSTON–(BUSINESS WIRE)–Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs. This builds on Form’s work with both […]